Humanigen Inc (HGENQ)
OTCMKTS: HGENQ · Delayed Price · USD
0.0002
0.00 (0.00%)
May 1, 2024, 4:00 PM EDT - Market closed
Humanigen Revenue
Humanigen had revenue of $1.70M in the twelve months ending March 31, 2023, down -59.01% year-over-year. Revenue in the quarter ending March 31, 2023 was $221.00K, a -78.67% decrease year-over-year. In the year 2022, Humanigen had annual revenue of $2.51M, a decrease of -30.07%.
Revenue (ttm)
$1.70M
Revenue Growth
-59.01%
P/S Ratio
0.01
Revenue / Employee
$283,167
Employees
6
Market Cap
23.82K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 2.51M | -1.08M | -30.07% |
Dec 31, 2021 | 3.60M | 3.28M | 1,052.24% |
Dec 31, 2020 | 312.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 44.00K | -6.05M | -99.28% |
Dec 31, 2012 | 6.10M | -14.16M | -69.89% |
Dec 31, 2011 | 20.26M | 2.54M | 14.36% |
Dec 31, 2010 | 17.71M | 17.12M | 2,907.13% |
Dec 31, 2009 | 589.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
HGENQ News
- 2 months ago - Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 4 months ago - COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy - Reuters
- 9 months ago - Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation - Newsfile Corp
- 11 months ago - Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress - Newsfile Corp
- 1 year ago - Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia - Newsfile Corp
- 1 year ago - Humanigen Reports Third Quarter 2022 Financial Results - Newsfile Corp
- 1 year ago - Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference - Newsfile Corp
- 1 year ago - Humanigen Announces Retention of SC&H Capital as Financial Advisor - Newsfile Corp